Eosinophil ablation and tumor development.
Tissue eosinophilia in squamous cell carcinoma has long been recognized; however, the role of eosinophils in tumor development remains unclear. Studies have reported both favorable and unfavorable prognoses for patients with tumors exhibiting tumor-associated tissue eosinophilia (TATE). This study seeks to elucidate the potential role of the eosinophil in squamous cell carcinoma development and provide an experimental model for future studies. The carcinogen-induced hamster oral cancer model was found to fulfill these objectives. Eosinophils progressively infiltrate into this carcinogen-induced oral cancer model. We now demonstrate that TATE is completely abolished by the use of an anti-interleukin-5 monoclonal antibody (mAb) preparation, TRFK-5. Clinical observations revealed that TRFK-5-treated hamsters exhibited smaller tumor burden and delayed onset of tumor development. The results suggest that anti-interleukin-5 antibody treatment may delay and/or inhibit tumor development, and that eosinophils may have a tumor-promoting role.
Wong
D T
DT
Department of Oral Medicine and Diagnostic Sciences, Harvard School of Dental Medicine, Boston, MA 02115, USA. david-wong@hms.harvard.edu
Bowen
S M
SM
Elovic
A
A
Gallagher
G T
GT
Weller
P F
PF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D006224:Cricetinae; D004802:Eosinophilia / Q000150:complications* / Q000473:pathology; D015848:Interleukin-5 / Q000276:immunology; D008297:Male; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy
D000911:Antibodies, Monoclonal; D015848:Interleukin-5